breast feeding and glp 1 Breastfeeding on GLP-1: Safety & Clinical Considerations – PlexusDx GLP-1 meds like Ozempic® and

Nvidia is donating open model weights, training data, and agent harness research to the effort, anchored by a new open-source project called the Nvidia Labs Object-Oriented Agent that has been published on GitHub

T.JeonJ

In 2022, Eli Lilly released their dual agonist, tirzepatide, a GLP-1 RA combined with glucose-dependent insulinotropic polypeptide (GIP) (as Mounjaro)

Theoretical Risks with Chronic Use Some concerns raised by clinicians and researchers include: Unregulated angiogenesis: Overstimulation of blood vessel growth could hypothetically support tumor progression in cancer-prone individuals Unknown hormonal crosstalk: While BPC-157 is non-hormonal, it interacts with systems (e.g., nitric oxide, dopamine) that may influence downstream signaling Immune tolerance or desensitization: Chronic exposure to any peptide could alter immune recognition or receptor sensitivity over time These concerns are theoretical , but they highlight why BPC-157 should not be used indefinitely or in uncontrolled cycles